Pelapresib/Ruxolitinib Reduces Spelonomegaly in MPN
A reduction in splenomegaly was observed when the combination of pelabresib plus ruxolitinib was used to treat patients with myelofibrosis.
Post-Hoc OPTIC Results Showcase Continued Safety in CP-CML
Ponatinib remains a safe treatment for patients with chronic-phase chronic myeloid leukemia.
Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma
Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.
Expert Highlights Potential Utility of Amivantamab in Advanced EGFR+ NSCLC
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
Artificial Intelligence Tool May Improve Oncology Multi-Trial Matching
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
FDA Acknowledges Zolbetuximab BLA Resubmission for CLDN18.2+ Gastric Cancer
The FDA has set a new Prescription Drug User Fee Act date of November 9, 2024, for zolbetuximab in this gastric cancer population.
41 A Case Series of Sarcomas
Asciminib Improves Efficacy Vs TKIs in Ph+ Chronic Myeloid Leukemia
The benefit-risk profile of asciminib may change the chronic myeloid leukemia treatment paradigm, according to Jorge E. Cortes, MD.
Lorlatinib Boosts Progression-Free Survival in ALK+ NSCLC
Lorlatinib may show “unprecedented” improvements in outcomes for those with advanced ALK-positive NSCLC, according to Benjamin J. Solomon, MBBS, PhD.
Nivolumab Combo Receives European Approval in Advanced Urothelial Carcinoma
The CheckMate -901 trial led to the approval of the nivolumab combination for unresectable or metastatic urothelial carcinoma in the European Union.
Comparative Efficacy of PTCY and ATG in GvHD Prophylaxis: Insights from Mismatched and Matched Donor Transplant Studies
Efficacy of post-transplant cyclophosphamide vs antithymocyte globulin remains a large discussion for patients with graft-vs-host disease.
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
ASTCT discusses Richter transformation and treatment options available for this population.
Nivolumab/Ipilimumab Yields Sustained Responses in Advanced HCC
The 5-year follow-up results from CheckMate 040 showed consistent responses with nivolumab/ipilimumab in advanced hepatocellular carcinoma.
FDA Approves Liso-cel in Relapsed/Refractory Mantle Cell Lymphoma
Findings from the TRANSCEND NHL 001 trial support the FDA approval of lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma.
Zanidatamab Earns FDA Priority Review in HER2+ Biliary Tract Cancer
The FDA has set a Prescription Drug User Fee Act date of November 29, 2024, for zanidatamab in this biliary tract cancer population.
Developing a Passion for Treating and Advancing Breast Cancer Care
Tiffany A. Traina, MD, FASCO, and Sherry Shen, MD, share their personal and professional journeys to becoming breast oncologists at Memorial Sloan Kettering Cancer Center.
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
FDA Grants Priority Review to Inavolisib in HR+/HER2– PIK3CA+ Breast Cancer
The FDA has set a Prescription Drug User Fee Act date of November 27, 2024, for the inavolisib-based combination in this breast cancer population.
Selpercatinib Earns Accelerated Approval in Pediatric RET+ Thyroid Cancer
Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
AFM24/Atezolizumab Earns FDA Fast Track Status in EGFR Wild-Type NSCLC
Data from the phase 1/2a AFM24-102 trial support the fast track designation for the AFM24 combination in EGFR wild-type non–small cell lung cancer.
Achieving Precision With Radiation Oncology Advancements in NSCLC
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
Assisted Reproductive Techniques Proven Safe in BRCA-Mutated Breast Cancer
Patients with BRCA-mutated breast cancer can safely undergo assisted reproductive techniques, according to an ESMO study.
Dato-DXd Improves Overall Survival Vs Chemo in Advanced Nonsquamous NSCLC
Investigators plan to present additional findings from the phase 3 TROPION-Lung01 trial at a future medical meeting.
Isatuximab Combo Earns FDA Priority Review in Transplant-Ineligible NDMM
The FDA has set a Prescription Drug User Fee Act Date of September 27, 2024, for the isatuximab combination in transplant-ineligible NDMM.
Minimizing Toxicity in NSCLC Management With Proton Beam Radiotherapy
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
Combining Immunotherapy With Radiation Oncology in NSCLC
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions
Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Metformin Use Reduces MPN Diagnosis Risk
Metformin, a type 2 diabetes drug, was found to reduce myeloproliferative neoplasm development.
